Rheumatology

Latest News

Juvenile arthritis awareness month | Image credit: Ocha Designs – stock.adobe.com
Adalimumab, Etanercept Biosimilars Deliver Real-World Results for Juvenile Idiopathic Arthritis

July 29th 2025

Real-world data suggest anti-TNF biosimilars for juvenile idiopathic arthritis offer comparable efficacy and safety to their brand name counterparts.

Group of doctors talking and looking at tablet | Image credit: Seventyfour – stock.adobe.com
Patients With RA and Cancer Seek More Clarity, Collaboration in Treatment Decisions

July 9th 2025

Older woman eating salad on yoga mat | Image credit: Prostock-studio – stock.adobe.com
Plant-Based Diet May Improve Stress-Related Metrics in Rheumatoid Arthritis

July 3rd 2025

Dentist consulting patient | Image credit: D Theron/peopleimages.com – stock.adobe.com
Dental Infections Pose Risks for Hospitalized Patients With Rheumatoid Arthritis

June 30th 2025

Doctor explaining notes to patient | Image credit: Minerva Studio – stock.adobe.com
Patient Materials for Rheumatoid Arthritis Often Miss Crucial Information

June 30th 2025

More News

Biologic Therapies and Pregnancy: Inflammation Control
November 26th 2018

Biologic Therapies and Pregnancy: Inflammation Control

Relationship Between Pregnancy and Autoimmune Disease
November 26th 2018

Relationship Between Pregnancy and Autoimmune Disease

TNF Inhibitors: Patient Selection
November 26th 2018

TNF Inhibitors: Patient Selection

Biologics and Small Molecules for Autoimmune Diseases
November 26th 2018

Biologics and Small Molecules for Autoimmune Diseases

Steroid-Sparing Therapies for Autoimmune Disease
November 26th 2018

Steroid-Sparing Therapies for Autoimmune Disease

Nonbiologic Therapy for Autoimmune Diseases
November 26th 2018

Nonbiologic Therapy for Autoimmune Diseases

Accurately Diagnosing an Autoimmune Disease
November 26th 2018

Accurately Diagnosing an Autoimmune Disease

Factors and Exposures Linked to Autoimmune Diseases
November 26th 2018

Factors and Exposures Linked to Autoimmune Diseases

Distinguishing Between Autoimmune Conditions: IBD
November 26th 2018

Distinguishing Between Autoimmune Conditions: IBD

Pathophysiology of Autoimmune Diseases and Inflammation
November 26th 2018

Pathophysiology of Autoimmune Diseases and Inflammation

Ultrasound Safer Than MRI to Monitor Rheumatoid Arthritis in Pregnancy
November 20th 2018

Ultrasound Safer Than MRI to Monitor Rheumatoid Arthritis in Pregnancy

David Bai, PharmD
Ultrasounds are a safer and equally effective diagnostic tool compared with magnetic resonance imaging (MRI) to diagnose and monitor pregnant women with suspected active rheumatoid arthritis (RA), according to a new report published in Radiology Case Reports.
Site Logo
July 12th 2018

Two-Year Adherence and Costs for Biologic Therapy for Rheumatoid Arthritis

Bradley S. Stolshek, PharmD Sally W. Wade, MPH Alex Mutebi, PhD, MSc Ajita P. De, MA, MPhil, MS Rolin L. Wade, MS Jason Yeaw, MPH
Adherence to newly initiated biologic therapy for rheumatoid arthritis is important for long-term adherence.
Switching Method of Action in RA Treatment After Anti-TNF Failure Associated With Lower Healthcare Costs
January 10th 2018

Switching Method of Action in RA Treatment After Anti-TNF Failure Associated With Lower Healthcare Costs

Kelly Davio
When patients with rheumatoid arthritis experience failure of an anti–tumor necrosis factor (anti-TNF) therapy, clinical guidelines support either cycling to a different anti-TNF agent or switching to a treatment with a different method of action (MOA). However, payers often require cycling of anti-TNF options before they will reimburse for treatments with a different MOA.
Biologics Associated With Lower Overall Risk of Malignancy in Patients With Early RA
January 3rd 2018

Biologics Associated With Lower Overall Risk of Malignancy in Patients With Early RA

Kelly Davio
In a new study, published in Arthritis Research & Therapy, a research team led by Soo-Kyung Cho, MD, sought to investigate the incidence of malignancy in early rheumatoid arthritis and found that the use of biologic disease-modifying anti-rheumatic drugs decreased the overall risk of developing malignancies, though it did not affect the risk of developing hematologic malignancies.
Site Logo
November 8th 2017

Federal Agencies Address the Dual Crises of Pain and Opioid Addiction

Kelly Davio
In a Tuesday panel discussion at The American College of Rheumatology’s 2017 Annual Meeting in San Diego, California, representatives from HHS, the National Institutes of Health (NIH), and the CDC outlined ongoing federal initiatives to address the parallel problems of pain and opioid addiction.
Site Logo
November 8th 2017

ACR and NPF Unveil New Clinical Guideline for Treating Psoriatic Arthritis

Kelly Davio
On Tuesday afternoon, the American College of Rheumatology (ACR) and the National Psoriasis Foundation (NPF) presented a draft of their new, jointly developed clinical guideline for treating psoriatic arthritis (PsA), at the ACR 2017 Annual Meeting.
Site Logo
November 7th 2017

Rheumatology Patients at Increased Risk for Cardiac Disease

Kelly Davio
During a session at the 2017 American College of Rheumatology Annual Meeting in San Diego, California, a cardiologist joined rheumatologists to give a detailed look at the relationship between rheumatic conditions and cardiovascular disease.
Site Logo
September 21st 2017

Certain Occupations Associated With an Increased Risk of Rheumatoid Arthritis

Alison Rodriguez
Occupations related to potential noxious airborne agents are related to an increased risk of rheumatoid arthritis (RA), according to recent research.
Site Logo
January 20th 2017

Exclusive Coverage of the American College of Rheumatology Annual Meeting Washington, DC November 11-16, 2016

Site Logo
November 16th 2016

Online Support Tools Teach Self-Management for Teens With Juvenile Arthritis

Christina Mattina
At the Annual Meeting of the American College of Rheumatology in Washington, DC, several experts presented their progress in harnessing technology to help teenagers and young adults manage their juvenile arthritis.
Site Logo
November 13th 2016

MACRA: Putting Together the Pieces for Practice

Be careful what you wish for:  SGR and FFS will be models of the past; the success of the APM and MIPS will rely on compensation, collaboration and participation; and, to date, much remains to be done in the development of quality-based payment reform under MACRA. 
Site Logo
November 13th 2016

Getting Telehealth Right: Engaging Patients and Providers

Telehealth broadly is about creating care connections across boundaries, care that encourages patients’ independence, prevention and wellness; and care that can be leveraged for needed interventions. If we get telehealth right we can reduce impact of what we know is a growing health workforce shortage and concurrently create a healthier, more engaged patient base.
Site Logo
April 30th 2014

Early Diagnosis Key to Getting Rheumatoid Arthritis Patients to 'Target, Leading Academic Physicians Agree

Two leading academic rheumatologists who took part in a live discussion with A. Mark Fendrick, MD, co-editor-in-chief of The American Journal of Managed Care, agreed that getting an accurate early diagnosis of rheumatoid arthritis (RA) is key to getting the patient started on disease modifying therapy. Today's goal, they said, is remission of the disease, not just managing symptoms.
Site Logo
July 14th 2011

Impact of Celecoxib Restrictions in Medicare Beneficiaries With Arthritis

Anthony M. Louder, PhD, RPh Ashish V. Joshi, PhD Amy T. Ball, PharmD Joseph C. Cappelleri, PhD Michael C. Deminski, MS, RPh Robert J. Sanchez, PhD
A formulary restriction policy in a Medicare population was associated with lower celecoxib utilization; however, higher gastrointestinal- and arthritis-related medical costs were observed.
Site Logo
December 1st 2007

The Future of Outcomes Measurement in Rheumatology

Robert M. Kaplan, PhD
ACR Supports Continued Use of Telemedicine and Reimbursement Parity After COVID-19 Crisis
December 1st 1997

ACR Supports Continued Use of Telemedicine and Reimbursement Parity After COVID-19 Crisis

Laura Joszt, MA
The widespread adoption of telemedicine during the coronavirus disease 2019 (COVID-19) pandemic, as well as reimbursement parity that was enacted by CMS, should be continued once the public health emergency passes, according to a new position statement by the American College of Rheumatology (ACR).
<1
...
67891011>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo